July 20 (Reuters) - Zynerba Pharmaceuticals Inc ::ZYNERBA PHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 4.06 MILLION COMMON SHARES PRICED AT $8.00PER SHARE.
Full Article
July 19 (Reuters) - Zynerba Pharmaceuticals Inc ::ZYNERBA PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.ZYNERBA PHARMACEUTICALS - ZYNERBA INTENDS TO USE NET PROCEEDS OF PROPOSED OFFERING TO SUPPORT CLINICAL DEVELOPMENT OF ZYN002, FOR ADDITIONAL RESEARCH AND DEVELOPMENT.
Full Article
July 12 (Reuters) - Zynerba Pharmaceuticals Inc ::ZYNERBA PHARMACEUTICALS ANNOUNCES NEW FAB-C PHASE 2 OPEN-LABEL DATA IN PATIENTS WITH FRAGILE X SYNDROME.ZYNERBA PHARMACEUTICALS - SIGNIFICANT IMPROVEMENTS IN BEHAVIORAL SYMPTOMS OBSERVED IN PATIENTS AND SUSTAINED THROUGH 38 WEEKS OF TREATMENT WITH ZYN002.ZYNERBA PHARMACEUTICALS INC - ZYN002 WAS WELL TOLERATED; NO SERIOUS ADVERSE EVENTS WERE REPORTED.
Full Article
July 5 (Reuters) - Zynerba Pharmaceuticals Inc ::ZYNERBA PHARMACEUTICALS ANNOUNCES TOP LINE RESULTS FROM ZYN001 THC-PRODRUG PATCH PHASE 1 STUDY.ZYNERBA PHARMACEUTICALS INC - ZYN001 WAS VERY WELL TOLERATED WITH MINIMAL SKIN ERYTHEMA.ZYNERBA PHARMACEUTICALS INC - THERE WERE NO SERIOUS ADVERSE EVENTS OR DISCONTINUATIONS FOR SUBJECTS RECEIVING ZYN001.ZYNERBA PHARMACEUTICALS - BELIEVES CASH & CASH EQUIVALENT POSITION AS OF MARCH 31, IS SUFFICIENT TO FUND OPERATIONS & CAPITAL REQUIREMENTS INTO H2 2019.
Full Article
Jan 3 (Reuters) - Zynerba Pharmaceuticals Inc ::ZYNERBA PHARMACEUTICALS PROVIDES 2018 CLINICAL AND CORPORATE UPDATE.ZYNERBA PHARMACEUTICALS INC - PLANS TO INITIATE PHASE 2 DEVELOPMENT OF ZYN001 IN TOURETTE SYNDROME BY YEAR END 2018.ZYNERBA - BELIEVES IT CAN FUND OPERATIONS AND CAPITAL REQUIREMENTS WELL INTO 2019.ZYNERBA PHARMACEUTICALS - WILL CONCENTRATE ITS FOCUS ON RARE AND NEAR-RARE NEUROLOGICAL AND PSYCHIATRIC DISORDERS WITH HIGH UNMET MEDICAL NEEDS.ZYNERBA - IN 2018, CO INTENDS TO DEVELOP ZYN002 IN PIVOTAL PHASE 2/3 PROGRAM IN FRAGILE X SYNDROME AND IN PHASE 2 PROGRAMS IN REFRACTORY EPILEPSIES.ZYNERBA PHARMACEUTICALS INC - PLAN TO INITIATE A PIVOTAL STUDY FOR ZYN002 IN FXS THAT SHOULD READ OUT IN 2019.
Full Article
Nov 14 (Reuters) - Zynerba Pharmaceuticals Inc :Zynerba Pharmaceuticals reports third quarter 2017 financial results and operational highlights.Q3 loss per share $0.63.Q3 earnings per share view $-0.59 -- Thomson Reuters I/B/E/S.Zynerba Pharmaceuticals - believes cash and cash equivalent position as of September 30, 2017 is sufficient to develop five phase 3-ready programs.Zynerba Pharmaceuticals Inc - believes that cash and cash equivalent position of as of September 30, 2017 is sufficient to fund operations into 2019.
Full Article
Zynerba Pharmaceuticals Inc : Entered into an open market sale agreement with Jefferies Llc, or Jefferies, as placement agent - SEC filing .Pursuant to agreement co may issue, sell shares of common stock in an aggregate offering price of up to $30.0 million.
Full Article
Zynerba Pharmaceuticals Inc :Zynerba Pharmaceuticals Inc files for mixed shelf of up to $150 million -SEC filing.
Full Article
Zynerba Pharmaceuticals Inc : Q2 loss per share $0.70 . Zynerba Pharmaceuticals reports second quarter 2016 financial results and organizational changes . Q2 earnings per share view $-0.54 -- Thomson Reuters I/B/E/S . Expects its existing cash and cash equivalents will fund its research and development programs and operations through 2017 .Jim Fickenscher will replace Richard Baron as Chief Financial Officer.
Full Article
Earnings vs. 
Estimates